<analysis>
**Action 1 (alignment program).** This action has four parts, and they carry different risks:
- **(d) Drafting the post-listing package** is trivial.
- **(a) Compaction-aware probing** is ordinary interpretability engineering. Reaching AUROC ≥0.75 on long transcripts (up from 0.66) within one month is uncertain. Signal lost at compaction boundaries is sometimes simply absent from the summaries.
- **(c) The overnight batch queue** competes with the capacity crunch. Akamai capacity arrives through Q1–Q2, so idle batch capacity is thin.
- **(b) Cross-grading at 1,000 runs** is feasible to run. Human review time limits how much can be adjudicated.
- Whether the gate becomes binding is modelled by Threat 2, so it is not counted here.
- Execution risk is moderate, driven mainly by (a) missing its target and (c) being starved of compute.

**Action 2 (Safety Commons).**
- The JFrog date is agreed, and the FMF working group already has it on the agenda.
- Named co-maintainers from OpenAI or Google DeepMind within the month is harder. They will respond substantively, possibly with objections, or offer their own suites.
- Sending the AISI offer is easy. Acceptance takes months.
- The staleness of the Artifactory issue is Threat 1 and is not counted here.
- The core deliverables ship through existing channels, so execution risk is modest.

**Action 3 (Mexico-misuse note and scans).**
- Counsel has blocked two voluntary publications. A misuse note is closer to ordinary threat-intelligence cadence, but its timing is near-S-1.
- The fallback reply to the reporter is likely to be approved.
- Converting the hospital draft into a signed pilot within a month is slow. Hospital procurement typically takes one to three months.
- Fifteen scans via a pre-signed template means persuading about 11 more customers' counsel to sign. That is plausible but not certain.
- The press consequences belong to Threat 3.

**Action 4 (Claude Works).**
- The launch is already approved and dated, so execution is low-risk.
- NASWA and two more state boards will not sign within the month; March is realistic at best.
- Free Pro for named insurer cohorts adds comms and legal friction and capacity cost. Legal may strike the naming.
- 25,000 users in six weeks without marketing is ambitious.
- Code abuse belongs to Threat 4.

**Action 5 (policy).**
- Endorsing a bipartisan bill is normal industry practice; Anthropic endorsed SB 53. However, registration counsel and the policy reorganisation have already stalled one item.
- Naming an owner for the folder is low-risk.
- Overall the risk is moderate.

**Action 6 (medical track).**
- This is a new project. An academic partner's agreement (DUA, IRB, institutional counsel) within about 4 weeks is unlikely.
- The OSF fallback touches Mythos outputs on pediatric therapeutics during registration. Bio-safety and legal review add delay.
- Risk is high.

**Threats.**
- **Threat 1.** The facts are credible and should be reconciled: the August–September Artifactory exploitation is real. There remains some chance that Anthropic's package covers a distinct variant, since JFrog engaged on a February date.
- **Threat 2.** Weak-grades-strong disagreement is very plausible. Release-gate changes are slow during registration.
- **Threat 3.** This requires either the note to run and be framed badly, or the story to break anyway.
- **Threat 4.** Promo abuse is routine, but referral codes limit it somewhat.
- **Threat 5.** DeepSeek V5 or a new Qwen is overdue. A February drop is roughly a coin flip, and a material narrowing of the gap is a bit less likely than that.
</analysis>

<action_odds>
Action 1 [Alignment program: probe fix, cross-grading, queue, post-listing package]: P(failure) 40%. Reason: the probe target is genuinely uncertain and batch compute is scarce during the crunch. Drafting and running cross-grading are routine. The gate decision is covered by Threat 2.

Action 2 [Safety Commons: JFrog ship, FMF stewardship, AISI held-out offer]: P(failure) 30%. Reason: the disclosure date and FMF agenda slot are already set, and the AISI offer goes through an existing partnership. Named co-maintainers from OpenAI or Google DeepMind are the weak link. Staleness is covered by Threat 1.

Action 3 [Mexico note, hospital pilot, 15 scans]: P(failure) 50%. Reason: counsel's record of blocking during registration, a hospital signature within a month is unlikely, and the scans depend on customers' counsel. The fallback reply lowers the chance of total failure.

Action 4 [Claude Works launch and scaling]: P(failure) 25%. Reason: the launch is approved and dated. The scaling targets (NASWA, 25,000 users, insurer-cohort naming) are ambitious and will likely be partly unmet, but the core deliverable is low-risk.

Action 5 [Incident Reporting Act endorsement and folder owner]: P(failure) 40%. Reason: endorsing a bill is normal, but registration counsel and the policy reorganisation have already stalled similar items. Naming an owner is easy.

Action 6 [Rare pediatric repurposing track]: P(failure) 60%. Reason: a new partner agreement in four weeks is unlikely, and the fallback faces bio and legal review of Mythos-derived therapeutic claims during registration.
</action_odds>

<threat_odds>
Threat 1 [Stale disclosure]: P(materialises) 40%. Adversary suggested 40%. I match it: the August–September exploitation facts are credible and reconciled into the world. Offsetting that, JFrog's engagement on a February date suggests the package may cover a distinct variant, and the severity is minor.

Threat 2 [Grader disagreement keeps the gate advisory]: P(materialises) 50%. Adversary suggested 45%. Slightly higher: the January false-positive rate was about 64%, review capacity is limited, and gate criteria change slowly during IPO registration under GPT-6 pressure.

Threat 3 [Pre-emptive note becomes the headline]: P(materialises) 25%. Adversary suggested 35% (or 20% if blocked). Lower overall: the note may be blocked or run only in trade press, and threat-intelligence notes have precedent. A mainstream negative story requires a pickup beyond the trade reporter.

Threat 4 [Claude Works verification gamed or bad framing]: P(materialises) 30%. Adversary suggested 35%/20%. Slightly lower: partner referral codes limit leaks, and legal will likely strip insurer naming. The combined chance of a leak-driven tightening or a critical piece is still meaningful.

Threat 5 [Chinese open weights narrow the gap]: P(materialises) 40%. Adversary suggested 45%. Slightly lower: a February release is roughly a coin flip, and a materially narrowed lag (3–5 months) with visible safety-suite and misuse consequences is a subset of that.
</threat_odds>
